PT  - JOURNAL ARTICLE
AU  - Emoke Papp
AU  - Anita Steib
AU  - Elhusseiny MM Abdelwahab
AU  - Judit Meggyes-Rapp
AU  - Laszlo Jakab
AU  - Gabor Smuk
AU  - Erzsebet Schlegl
AU  - Judit Moldvay
AU  - Veronika Sárosi
AU  - Judit E Pongracz
TI  - Feasibility study of in vitro drug sensitivity assay of advanced non-small cell lung adenocarcinomas
AID  - 10.1136/bmjresp-2019-000505
DP  - 2020 Jun 01
TA  - BMJ Open Respiratory Research
PG  - e000505
VI  - 7
IP  - 1
4099  - http://bmjopenrespres.bmj.com/content/7/1/e000505.short
4100  - http://bmjopenrespres.bmj.com/content/7/1/e000505.full
SO  - BMJ Open Resp Res2020 Jun 01; 7
AB  - Background Despite improved screening techniques, diagnosis of lung cancer is often late and its prognosis is poor. In the present study, in vitro chemosensitivity of solid tumours and pleural effusions of lung adenocarcinomas were analysed and compared with clinical drug response.Methods Tumour cells were isolated from resected solid tumours or pleural effusions, and cryopreserved. Three-dimensional (3D) tissue aggregate cultures were set up when the oncoteam reached therapy decision for individual patients. The aggregates were then treated with the selected drug or drug combination and in vitro chemosensitivity was tested individually measuring ATP levels. The clinical response to therapy was assessed by standard clinical evaluation over an 18 months period.Results Based on the data, the in vitro chemosensitivity test results correlate well with clinical treatment response.Conclusions Such tests if implemented into the clinical decision making process might allow the selection of an even more individualised chemotherapy protocol which could lead to better therapy response.